News
July 2014: ReveraGen Drug Will Move to Human Testing
ReveraGen BioPharma, based in Silver Spring, Md., is moving ahead with a phase 1 trial of an experimental compound in development to treat Duchenne muscular dystrophy, made possible by a $2 million grant from U.S.-based MDA and three United Kingdom-based
More >July 2014: International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug
Four nonprofit organizations, the Muscular Dystrophy Association (USA), Joining Jack Foundation (UK), The Duchenne Research Fund (UK) and the Duchenne Children’s Trust (UK) have joined together to provide Phase 1 clinical trial funding for the first-in-human studies of VBP15, the
More >